Araceli Biosciences Introduces Matt Beaudet as New President and Chief Executive Officer

May 6, 2024 1:20 PM

PORTLAND, OR / ACCESSWIRE / May 6, 2024 / Araceli Biosciences, experts in cell-based screening and analysis technologies announced that their Board of Directors has appointed Matthew (Matt) Beaudet as the company's new CEO. Matt brings a distinguished career spanning over two decades in leadership across several influential companies in the biotech industry, such as Molecular Probes, Invitrogen, and Life Technologies, culminating in a...

Read more

Former Disney & Airbnb Executive Catherine Powell Joins Board for Psychedelic Biotech Company Inner State, Inc.

May 6, 2024 11:00 AM

LOS ANGELES, CA / ACCESSWIRE / May 6, 2024 / Inner State, Inc. (Inner State), a psychedelic biotech company dedicated to advancing women's health and wellness outcomes, appointed former Airbnb and Disney executive Catherine Powell to the Board of Directors.Inner State Board Member Catherine Powell "Catherine brings an extensive executive portfolio to Inner State's board and is recognized for her ability to manage complex operations at scale,"...

Read more

Resolutions at BioInvent's Annual General Meeting 2024

May 3, 2024 11:30 AM

LUND, SWEDEN / ACCESSWIRE / May 3, 2024 / BioInvent International (STO:BINV)The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Laura Lassouw-Polman as new Board member, to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program.The AGM...

Read more

Multiple Presentations at ASGCT 2024 Highlight Form Bio’s Expertise in AI-Based AAV Gene Therapy Design and Development

May 3, 2024 8:00 AM

Presentations Focused on How AI is Leveraged to Optimize Gene Therapy Construct Designs for Safety, Yield and Efficacy - Resulting in Faster Delivery to Market With a Higher Probability of SuccessSAN FRANCISCO, CA / ACCESSWIRE / May 3, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, today announced that it will deliver multiple presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th...

Read more

Interim Report January-March 2024

May 3, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for first quarter 2024.Important events during the first quarterIn January, Vicore announced discontinuation of the preclinical IMiD program to focus resources...

Read more

Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment

May 2, 2024 9:40 AM

ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillment LLC ("TCF"), to serve the new ENZC initiative focusing on licensing of products in the medical devices, nutraceuticals, medical testing and other well being and safety products.The newly formed company, ETC Marketing, will be jointly owned with...

Read more

CARDIO inCode-Score (CIC-Score) Presentation at the European Society of Cardiology

May 1, 2024 10:00 AM

Preventive Cardiology Congress Athens 2024OXFORD, ENGLAND / ACCESSWIRE / May 1, 2024 / GENinCode Plc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, gave details of a presentation by Kaiser Permanente at the European Society of Cardiology (ESC) Preventive Cardiology congress in Athens, Greece, on the ‘Joint consideration of low-density lipoprotein cholesterol ("LDL-C") and polygenic risk for...

Read more

NovAccess Global Announces New License to Advance its Immunotherapy Platform

April 30, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medical Center to further advance the Company's immunotherapy platform. The license pertains to the use of Isocitrate Dehydrogenase-1 (IDH1), a protein...

Read more

Tharimmune To Participate in Two Upcoming Investor Conferences in May

April 30, 2024 8:31 AM

BRIDGEWATER, NJ / ACCESSWIRE / April 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced that management will be participating in two investor conferences in May.Randy Milby, Chief Executive Officer, will be presenting at the Planet MicroCap Showcase: VEGAS 2024 being held at the Paris Hotel &...

Read more

Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema

April 30, 2024 7:00 AM

MENLO PARK, CA / ACCESSWIRE / April 30, 2024 / Emmetrope Ophthalmics LLC ("Emmecell"), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of serious eye diseases, today announced final dose administration for the last patient in its U.S. randomized, double-masked, multi-center trial assessing the safety and efficacy of EO2002 for the treatment of corneal edema.Emmecell Logo...

Read more

Moolec Announces New Patent Granting in the United States for Molecular Farming Platform

April 30, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / April 30, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a Molecular Farming food-ingredient company, announced today the granting of a patent family in the United States for its SPC2 product produced in safflower with Molecular Farming technology. This new patent adjudication will give the company, through its U.S. sole-owned subsidiary AG Biomolecules LLC, exclusivity for the use of the technology until...

Read more

Genflow Biosciences PLC Announces Total Voting Rights

April 30, 2024 2:05 AM

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.Total Voting RightsLONDON, UK /...

Read more

Biophytis is Deploying its Partnership Strategy in Obesity

April 29, 2024 9:00 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the implementation of a dedicated strategy for partner search in obesity.Biophytis is continually working on the search for partners thanks to a sound strategy and action plan, with...

Read more

Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.

April 29, 2024 7:00 AM

- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April 29, 2024 / Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTC PINK:CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent...

Read more

Radiance Biopharma to Present at LSX World Congress 2024

April 26, 2024 12:10 PM

Radiance Biopharma ("Radiance" or the "Company"), a biopharmaceutical company specializing in the development of novel Antibody Drug Conjugates (ADCs) and Bispecific ADCs (BsADCs) treatments for cancers, today announced that Robert Brooks, JD, Chief Executive Officer of Radiance will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 11:15AM (GMT+1) in London, England.In addition to the presentation, Mr. Brooks will be available...

Read more

Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team

April 25, 2024 9:45 AM

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.Watch the "What This Means" video hereAs part of this "What This Means" segment, Walter Klemp, Chairman and Chief Executive...

Read more

TuHURA Biosciences to Present Its IFx-2.0 Personalized Cancer Vaccine Clinical Trial Results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 25, 2024 9:00 AM

TAMPA, FL and SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its IFx-2.0 Phase 1b clinical trial results have been accepted for poster presentation at the 2024 ASCO Annual Meeting taking place May 31-June 4, 2024 in Chicago, IL.Details of the presentation are...

Read more

Ondine Biomedical Inc Announces New Study Confirms Nose Is Key Source of Infection

April 25, 2024 2:00 AM

Ondine Biomedical Inc. (LON:OBI), the Canadian life sciences company pioneering light-activated antimicrobial treatments, announces new independent research published in the journal Science Translational Medicine showing that 86% of surgical site infections (SSIs)! after spinal surgery are caused by bacteria from the patient's own nose, skin, or gut. The study, "Contribution of the patient microbiome to surgical site infection and antibiotic...

Read more

Hemogenyx Pharmaceuticals PLC Announces Final Results

April 25, 2024 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2023. The Annual Report is available to view on the Company's web site at https://hemogenyx.com.Key Highlights· Investigational New Drug ("IND") application submitted in May 2023 seeking authorisation from the U.S. Food and Drug Administration ("FDA")...

Read more

Tiger Aesthetics Medical, LLC Acquires Assets of Sientra, Inc.

April 24, 2024 5:45 PM

Focus on Regenerative Medicine Combined with Best-in-Class Aesthetics Device OfferingFRANKLIN, WI / ACCESSWIRE / April 24, 2024 / Tiger Aesthetics Medical, LLC today announced its acquisition of substantially all of the assets associated with the Sientra Inc. breast implant business. This strategic acquisition will complement Tiger Aesthetics' upcoming adipose cell and tissue product launches designed to provide new treatment options for plastic...

Read more